-SEC Filing
Barclays Maintains Equal-Weight on Blueprint Medicines, Lowers Price Target to $58
Barclays analyst Peter Lawson maintains Blueprint Medicines (NASDAQ:BPMC) with a Equal-Weight and lowers the price target from $70 to $58.
Related Posts
What’s Going On With Prestige Weath (PWM) Stock Monday?
Prestige Wealth, Inc. (NASDAQ: PWM) shares are volatile Monday. The stock has been halted multiple times in early trading. Here's a look at what's going on.
Bitcoin, Ethereum, Dogecoin Crash On Rising Treasury Yields — Analyst Says Apex Coin Could Fall Below $17,600 If This Happens
Major coins dropped sharply Tuesday evening as the global cryptocurrency market cap declined 4.2% to $948 billion at 8:30 p.m. EDT.
Activision Blizzard, Argenx And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures traded mixed this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session.